{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:02:42Z","timestamp":1790326962403,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pembrolizumab has demonstrated efficacy in improving disease-free survival (DFS) and overall survival (OS) as adjuvant therapy in clear cell renal cell carcinoma (ccRCC) at a higher risk of recurrence. However, real-world data on its effectiveness and safety remain limited. This study evaluates DFS, OS and severe adverse events (SAEs) associated with adjuvant pembrolizumab in a multicenter international cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis included 311 ccRCC patients treated with adjuvant pembrolizumab across 40 hospitals in 12 countries from the ARON-1 dataset. Eligible patients had histologically confirmed ccRCC with high relapse risk and received up to 17 cycles of pembrolizumab. The primary objective was DFS, with OS and safety as secondary objectives. Kaplan\u2013Meier survival estimates, Cox proportional hazards models and log-rank tests were used for statistical analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At a median follow-up of 15.4-month, 2-year OS and DFS rates were 95% and 69%, respectively. Recurrence occurred in 20% of patients, primarily in the lungs (11%) and bones (5%). DFS was significantly impaired in patients\u2009&lt;\u200965\u00a0years (HR 2.14,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), N1 disease (HR 5.42,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) and sarcomatoid dedifferentiation (HR 2.54,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). SAEs led to 19% treatment discontinuation, with colitis (4%), hypertransaminasemia (4%) and nephritis (3%) as the most common events. The study\u2019s retrospective nature and short follow-up limit long-term outcome assessments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This large real-world study confirms pembrolizumab\u2019s effectiveness and manageable safety profile in the adjuvant setting for intermediate-high and high-risk ccRCC. Further research is needed to refine patient selection strategies and evaluate long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-025-04230-w","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:42:54Z","timestamp":1763134974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study"],"prefix":"10.1007","volume":"74","author":[{"given":"Ray Manneh","family":"Kopp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Schieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jind\u0159ich","family":"Kopeck\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Kucharz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin W.","family":"Myint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Bolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Rosellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Zgura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Partl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Akova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"10451","key":"4230_CR1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","volume":"404","author":"M Young","year":"2024","unstructured":"Young M, Jackson-Spence F, Beltran L et al (2024) Renal cell carcinoma. Lancet 404(10451):476\u2013491. https:\/\/doi.org\/10.1016\/S0140-6736(24)00917-6","journal-title":"Lancet"},{"key":"4230_CR2","doi-asserted-by":"publisher","first-page":"102558","DOI":"10.1016\/j.ctrv.2023.102558","volume":"116","author":"M Rizzo","year":"2023","unstructured":"Rizzo M, Cali\u00f2 A, Brunelli M et al (2023) Clinico-pathological implications of the 2022 WHO renal cell carcinoma classification. Cancer Treat Rev 116:102558. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102558","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"4230_CR3","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","volume":"24","author":"YW Chen","year":"2023","unstructured":"Chen YW, Wang L, Panian J et al (2023) Treatment landscape of renal cell carcinoma. Curr Treat Options Oncol 24(12):1889\u20131916. https:\/\/doi.org\/10.1007\/s11864-023-01161-5","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"4230_CR4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.eururo.2018.01.005","volume":"73","author":"BC Leibovich","year":"2018","unstructured":"Leibovich BC, Lohse CM, Cheville JC et al (2018) Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 73(5):772\u2013780. https:\/\/doi.org\/10.1016\/j.eururo.2018.01.005","journal-title":"Eur Urol"},{"issue":"7","key":"4230_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/iju.14859","volume":"29","author":"S Juul","year":"2022","unstructured":"Juul S, Donskov F, Clark PE, Lund L, Azawi NH (2022) GRade age nodes and tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: a nationwide study. Int J Urol 29(7):641\u2013645. https:\/\/doi.org\/10.1111\/iju.14859","journal-title":"Int J Urol"},{"issue":"8","key":"4230_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH et al (2021) Adjuvant Pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 385(8):683\u2013694. https:\/\/doi.org\/10.1056\/NEJMoa2106391","journal-title":"N Engl J Med"},{"issue":"10","key":"4230_CR7","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/jamaoncol.2023.2174","volume":"9","author":"A Necchi","year":"2023","unstructured":"Necchi A, Faltas BM, Slovin SF et al (2023) Immunotherapy in the treatment of localized genitourinary cancers. JAMA Oncol 9(10):1447\u20131454. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2174","journal-title":"JAMA Oncol"},{"issue":"2","key":"4230_CR8","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/j.clgc.2018.12.01","volume":"17","author":"F Massari","year":"2019","unstructured":"Massari F, Di Nunno V, Mollica V, Graham J, Gatto L, Heng D (2019) Adjuvant tyrosine kinase inhibitors in treatment of renal cell carcinoma: a meta-analysis of available clinical trials. Clin Genitourin Cancer 17(2):e339\u2013e344. https:\/\/doi.org\/10.1016\/j.clgc.2018.12.01","journal-title":"Clin Genitourin Cancer"},{"issue":"15","key":"4230_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Tomczak P, Park SH et al (2024) Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med 390(15):1359\u20131371. https:\/\/doi.org\/10.1056\/NEJMoa2312695","journal-title":"N Engl J Med"},{"issue":"12","key":"4230_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/14712598.2023.2294001","volume":"23","author":"M Alevizakos","year":"2023","unstructured":"Alevizakos M, McDermott D (2023) Adjuvant immunotherapy for locally advanced renal cell carcinoma. Expert Opin Biol Ther 23(12):1265\u20131275. https:\/\/doi.org\/10.1080\/14712598.2023.2294001","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"4230_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41585-024-00896-6","volume":"21","author":"F Massari","year":"2024","unstructured":"Massari F, Rosellini M, Mollica V (2024) Overall survival with adjuvant pembrolizumab in renal cell carcinoma\u2014the shock of the lightning. Nat Rev Urol 21(10):578\u2013579. https:\/\/doi.org\/10.1038\/s41585-024-00896-6","journal-title":"Nat Rev Urol"},{"issue":"3","key":"4230_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","volume":"20","author":"M Rosellini","year":"2023","unstructured":"Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F (2023) Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol 20(3):133\u2013157. https:\/\/doi.org\/10.1038\/s41585-022-00676-0","journal-title":"Nat Rev Urol"},{"issue":"5","key":"4230_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.euo.2024.03.01","volume":"7","author":"F Massari","year":"2024","unstructured":"Massari F, Mollica V, Fiala O et al (2024) Papillary renal cell carcinoma: outcomes for patients receiving first-line immune-based combinations or tyrosine kinase inhibitors from the ARON-1 study. Eur Urol Oncol 7(5):1123\u20131131. https:\/\/doi.org\/10.1016\/j.euo.2024.03.01","journal-title":"Eur Urol Oncol"},{"key":"4230_CR14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.23736\/S2724-6051.23.05369-7","volume":"75","author":"C Porta","year":"2023","unstructured":"Porta C, Bamias A, Zakopoulou R et al (2023) Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. Minerva Urol Nefrol 75:460\u2013470. https:\/\/doi.org\/10.23736\/S2724-6051.23.05369-7","journal-title":"Minerva Urol Nefrol"},{"key":"4230_CR15","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/j.clgc.2023.03.006","volume":"21","author":"M Santoni","year":"2023","unstructured":"Santoni M, Massari F, Myint ZW et al (2023) Clinico-pathological features influencing the prognostic role of body mass index in patients with advanced renal cell carcinoma treated by immuno-oncology combinations (ARON-1). Clin Genitourin Cancer 21:e309\u2013e319. https:\/\/doi.org\/10.1016\/j.clgc.2023.03.006","journal-title":"Clin Genitourin Cancer"},{"key":"4230_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.euo.2023.07.003","volume":"7","author":"M Santoni","year":"2024","unstructured":"Santoni M, Buti S, Myint ZW et al (2024) Real-world outcome of patients with advanced renal cell carcinoma and intermediate or poor-risk International metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: differential effectiveness by risk group? Eur Urol Oncol 7:102\u2013111. https:\/\/doi.org\/10.1016\/j.euo.2023.07.003","journal-title":"Eur Urol Oncol"},{"key":"4230_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11523-023-00978-2","volume":"18","author":"M Santoni","year":"2023","unstructured":"Santoni M, Massari F, Myint ZW et al (2023) Global real-world outcomes of patients receiving immuno-oncology combinations for advanced renal cell carcinoma: the ARON-1 study. Target Oncol 18:559\u2013570. https:\/\/doi.org\/10.1007\/s11523-023-00978-2","journal-title":"Target Oncol"},{"key":"4230_CR18","doi-asserted-by":"publisher","DOI":"10.1159\/000543278","author":"A Mattigk","year":"2024","unstructured":"Mattigk A, Cano Garcia C, Kl\u00fcmper N et al (2024) Adjuvant therapy with Pembrolizumab in renal cell carcinoma: real-world experiences from a retrospective multi-institutional cohort. Urol Int. https:\/\/doi.org\/10.1159\/000543278","journal-title":"Urol Int"},{"key":"4230_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/JCO.2025.43.5_suppl.480","volume":"43","author":"R Uzzo","year":"2025","unstructured":"Uzzo R, Bhattacharya R, Bupathi M et al (2025) Real-world analysis of Pembrolizumab utilization and characteristics of patients being prescribed treatment in early stage RCC. J Clin Oncol 43:5","journal-title":"J Clin Oncol"},{"issue":"10","key":"4230_CR20","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/cncr.31955","volume":"125","author":"R Mamtani","year":"2019","unstructured":"Mamtani R, Wang XV, Gyawali B et al (2019) Association between age and sex and mortality after adjuvant therapy for renal cancer. Cancer 125(10):1637\u20131644. https:\/\/doi.org\/10.1002\/cncr.31955","journal-title":"Cancer"},{"issue":"11","key":"4230_CR21","doi-asserted-by":"publisher","first-page":"661.e7","DOI":"10.1016\/j.urolonc.2017.06.060","volume":"35","author":"T Chandrasekar","year":"2017","unstructured":"Chandrasekar T, Klaassen Z, Goldberg H, Kulkarni GS, Hamilton RJ, Fleshner NE (2017) Metastatic renal cell carcinoma: patterns and predictors of metastases-a contemporary population-based series. Urol Oncol 35(11):661.e7-661.e14. https:\/\/doi.org\/10.1016\/j.urolonc.2017.06.060","journal-title":"Urol Oncol"},{"issue":"4","key":"4230_CR22","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/annonc\/mdq554","volume":"22","author":"B Beuselinck","year":"2011","unstructured":"Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22(4):794\u2013800. https:\/\/doi.org\/10.1093\/annonc\/mdq554","journal-title":"Ann Oncol"},{"issue":"14","key":"4230_CR23","doi-asserted-by":"publisher","first-page":"e176230","DOI":"10.1172\/JCI176230","volume":"134","author":"S Gulati","year":"2024","unstructured":"Gulati S, Barata PC, Elliott A et al (2024) Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma. J Clin Invest 134(14):e176230. https:\/\/doi.org\/10.1172\/JCI176230","journal-title":"J Clin Invest"},{"issue":"3","key":"4230_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic S, Xu H, Litchfield K et al (2018) Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173(3):581-594.e12. https:\/\/doi.org\/10.1016\/j.cell.2018.03.057","journal-title":"Cell"},{"issue":"6","key":"4230_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.eururo.2024.07.016","volume":"86","author":"T El Zarif","year":"2024","unstructured":"El Zarif T, Semaan K, Xie W et al (2024) First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma: an international multicenter study. Eur Urol 86(6):503\u2013512. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.016","journal-title":"Eur Urol"},{"issue":"6","key":"4230_CR26","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1016\/j.clgc.2021.04.006","volume":"19","author":"JA Shaya","year":"2021","unstructured":"Shaya JA, Lin X, Weise N et al (2021) Prognostic significance of pancreatic metastases in patients with advanced renal cell carcinoma treated with systemic therapy. Clin Genitourin Cancer 19(6):e367\u2013e373. https:\/\/doi.org\/10.1016\/j.clgc.2021.04.006","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"4230_CR27","doi-asserted-by":"publisher","first-page":"e2021869","DOI":"10.1001\/jamanetworkopen.2020.21869","volume":"4","author":"S Dudani","year":"2021","unstructured":"Dudani S, de Velasco G, Wells JC et al (2021) Evaluation of clear cell papillary and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 4(1):e2021869. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.21869","journal-title":"JAMA Netw Open"},{"issue":"11","key":"4230_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","volume":"17","author":"C Robert","year":"2020","unstructured":"Robert C, Marabelle A, Herrscher H et al (2020) Immunotherapy discontinuation\u2014how and when? Data from melanoma as a paradigm. Nat Rev Clin Oncol 17(11):707\u2013715. https:\/\/doi.org\/10.1038\/s41571-020-0399-6","journal-title":"Nat Rev Clin Oncol"},{"key":"4230_CR29","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1200\/JCO.2024.42.16_suppl.4506","volume":"4216","author":"L Albiges","year":"2024","unstructured":"Albiges L, Bex A, Su\u00e1rez C et al (2024) Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: a randomized phase 3 study of adjuvant atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection. J Clin Oncol 4216:4506. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4506","journal-title":"J Clin Oncol"},{"issue":"3","key":"4230_CR30","first-page":"291","volume":"109","author":"A Mattigk","year":"2025","unstructured":"Mattigk A, Cano Garcia C, Kl\u00fcmper N et al (2025) Adjuvant therapy with Pembrolizumab in renal cell carcinoma: real-world experiences from a retrospective. Multi-Institutional Cohort Urol Int 109(3):291\u2013298","journal-title":"Multi-Institutional Cohort Urol Int"},{"issue":"5","key":"4230_CR31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1200\/JCO.2025.43.5_suppl.480","volume":"43","author":"R Uzzo","year":"2025","unstructured":"Uzzo R, Bhattacharya R, Bupathi M et al (2025) Real-world analysis of Pembrolizumab utilization and characteristics of patients being prescribed treatment in early stage RCC. J Clin Oncol 43(5):480","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04230-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04230-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04230-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:20Z","timestamp":1764600320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04230-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4230"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04230-w","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"374"}}